UK-based pharmaceutical giant AstraZeneca and the University of Oxford have confirmed their phase-three experimental coronavirus vaccine trial has shown an average efficacy of 70 percent. However, one dosing regimen showed an effectiveness of 90 percent when trial participants received a half dose, followed by a full dose at least one month apart. This comes after both Pfizer and Moderna reported that their respective preliminary trial Covid-19 vaccines were around 95 percent effective.